Clinical Trials

60 enrolled

NSCLC

NCT07185997 2026-05-11

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

480 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT06613633 2026-04-29

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Completed

4,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07548060 2026-04-23

TROP-LUNG

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07517640 2026-04-08

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07348965 2026-04-02

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Recruiting

42 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Phase 1 Recruiting

288 enrolled

Advanced Non-small Cell Lung Cancer

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

63 enrolled

Phase 1 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

60 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07314216 2026-01-06

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

30 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04858958 2025-11-19

FAVOUR

30 enrolled

Phase 2 Active not recruiting

NSCLC

NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

100 enrolled

NSCLC

NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Phase 1/2 Recruiting

300 enrolled

Advanced Lung Cancer

NCT07193160 2025-09-25

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07087223 2025-07-25

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Phase 1/2 Recruiting

42 enrolled

Non Small Cell Lung Cancer NSCLC

NCT06962865 2025-07-16

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

80 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05607550 2025-06-22

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

398 enrolled